HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Targeted radio-immunotherapy with Bexxar produces durable remissions in patients with late stage low grade non-Hodgkin's lymphomas.

Abstract
Patients with low grade (LG) non-Hodgkin's lymphomas (NHLs) typically have a median survival of 8-10 years during which they sustain a series of responses and relapses to therapy. More than 95% of B-cell NHLs express the CD20 surface antigen, affording opportunities for CD20-directed therapy of NHL. Since 1990, 5 trials have tested the safety and efficacy of the murine CD20 MAb Tositumomab and Iodine I 131 Tositumomab (Bexxar therapeutic regimen) in 250 patients with relapsed, refractory, or transformed LG NHL. The I-131 irradiates MAb-bound cells and those within the path length of the isotope. Response rates were 56% (overall) and 30% (complete). With a median follow-up of 44.6 months, 30% of the patients achieved a long-term, durable response; median time to progressive disease or death was 5 years. Thus, a single treatment with Bexxar may produce durable responses and partially reverse the natural history of LG NHL.
AuthorsRobert L Capizzi
JournalTransactions of the American Clinical and Climatological Association (Trans Am Clin Climatol Assoc) Vol. 115 Pg. 255-72 ( 2004) ISSN: 0065-7778 [Print] United States
PMID17060972 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
Chemical References
  • Antibodies, Monoclonal
  • Antigens, CD20
  • Iodine Radioisotopes
  • tositumomab I-131
Topics
  • Antibodies, Monoclonal (adverse effects, therapeutic use)
  • Antigens, CD20 (metabolism)
  • Clinical Trials as Topic
  • Humans
  • Iodine Radioisotopes (therapeutic use)
  • Lymphoma, B-Cell (therapy)
  • Lymphoma, Non-Hodgkin (classification, pathology, therapy)
  • Neoplasm Staging
  • Radioimmunotherapy
  • Remission Induction

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: